Skip to main content
. 2019 Mar 15;42:326–339. doi: 10.1016/j.ebiom.2019.03.019

Fig. 3.

Fig. 3

CsA suppresses crizotinib-induced activation of Erk1/2. (a) SPC-A1 and PC-9 cells were treated with crizotinib in the presence or absence of CsA for 48 h, after which they were examined for the expression of phosphorylated and total MET, STAT3, AKT, Erk1/2 and K-ras by immunoblotting. (b) Cells were treated with 2 μM CsA for the indicated intervals and then were examined for the expression of phosphorylated and total Erk1/2 by immunoblotting. (c) Cells were treated with the indicated concentration of CsA for 48 h and then were examined for the expression of phospho- and total Erk1/2. (d) Cells were treated with crizotinib for the indicated intervals and then examined for the expression of phospho- and total Erk1/2. (e) SPC-A1 and PC-9 cells were treated with the indicated concentration of crizotinib for 24 h and then were examined for the expression of phospho- and total Erk1/2. (f) Cells were treated with crizotinib in the presence or absence of CsA (2 μM) for the indicated intervals and then were examined for the expression of phosphorylated and total Erk1/2 by immunoblotting.